You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Checkpoint blockade

Showing 1 - 25 of 2,441
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma Trial in Orlando (Exercise Test)

Not yet recruiting
  • Cutaneous Melanoma
  • +2 more
  • Exercise Test
  • Orlando, Florida
    AdventHealth Translational Research Institute
Aug 18, 2023

Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma Trial in Tampa (Excerise, Checkpoint Blockade,

Recruiting
  • Cutaneous Melanoma
  • +2 more
  • Excerise
  • Checkpoint Blockade, Immune
  • Tampa, Florida
    Moffitt Cancer Center
Sep 21, 2022

PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging

Completed
  • Non-small Cell Lung Cancer (NSCLC)
    • Nîmes, France
      Jean-Paul BEREGI
    Jan 25, 2023

    Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Orange, Chicago, Boston (rHSC-DIPGVax,

    Recruiting
    • Diffuse Intrinsic Pontine Glioma
    • Diffuse Midline Glioma, H3 K27M-Mutant
    • rHSC-DIPGVax
    • +2 more
    • Orange, California
    • +2 more
    Nov 10, 2022

    Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma Trial in Aurora (doxorubicin with AGEN1884 and AGEN2034)

    Recruiting
    • Metastatic Soft Tissue Sarcoma
    • Advanced Soft Tissue Sarcoma
    • doxorubicin with AGEN1884 and AGEN2034
    • Aurora, Colorado
      University of Colorado Hospital
    Jan 4, 2023

    Locally Advanced Pancreatic Adenocarcinoma Trial in Houston (SD-101, pebrolizumab)

    Recruiting
    • Locally Advanced Pancreatic Adenocarcinoma
    • Houston, Texas
      MD Anderson Cancer Center
    Nov 18, 2022

    Glioblastoma Trial in Atlanta, Bethesda (Nivolumab, BMS-986016)

    Recruiting
    • Glioblastoma
    • Atlanta, Georgia
    • +1 more
    Sep 21, 2022

    MDS, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Ann Arbor (Pembrolizumab)

    Terminated
    • Myelodysplastic Syndromes
    • +2 more
    • Ann Arbor, Michigan
      University of Michigan Cancer Center
    Nov 1, 2022

    Urothelial Carcinoma Trial in Amsterdam (Tremelimumab, Durvalumab, Paclitaxel)

    Active, not recruiting
    • Urothelial Carcinoma
    • Amsterdam, Netherlands
      Antoni van Leeuwenhoek Ziekenhuis
    Jul 7, 2022

    Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in Houston (SD-101, Pembrolizumab, Nivolumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Intrahepatic Cholangiocarcinoma
    • New York, New York
    • +3 more
    Oct 19, 2022

    Response to Immune Checkpoint Blockade in Metastatic Melanoma

    Completed
    • Melanoma
    • F-FDG PET/CT
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Jul 7, 2022

    Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

    Active, not recruiting
    • Gastrointestinal Cancer
    • New York, New York
    • +1 more
    Nov 29, 2022

    Metastatic Cancer Trial in La Jolla (CBI, CBI plus SBRT)

    Active, not recruiting
    • Metastatic Cancer
    • La Jolla, California
      UCSD Moores Cancer Center
    May 16, 2022

    Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

    Not yet recruiting
    • Resectable Hepatocellular Carcinoma
    • (no location specified)
    Dec 12, 2022

    Metastatic Uveal Melanoma in the Liver Trial in United States (SD-101, Nivolumab, Ipilimumab)

    Recruiting
    • Metastatic Uveal Melanoma in the Liver
    • Los Angeles, California
    • +9 more
    Jan 27, 2023

    Ovarian Cancer Recurrent Trial in Pittsburgh (Rintatolimod, Pembrolizumab, Cisplatin)

    Recruiting
    • Ovarian Cancer Recurrent
    • Pittsburgh, Pennsylvania
      Magee-Womens Hospital of UPMC
    Mar 3, 2022

    Metastatic Breast Cancer Trial in Amsterdam (Nivolumab, Cisplatin, Low dose doxorubicin)

    Recruiting
    • Metastatic Breast Cancer
    • Amsterdam, Netherlands
      Antoni van Leeuwenhoek
    Mar 21, 2022

    Colonic Tumors, Colorectal Tumors Trial in Detroit, New York, Cincinnati (GRT-C901, GRT-R902, Atezolizumab)

    Recruiting
    • Colonic Neoplasms
    • Colorectal Neoplasms
    • Detroit, Michigan
    • +2 more
    Aug 1, 2022

    Primary and Metastatic Tumors in Renal Cell Carcinoma and

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • Immune checkpoint inhibitor targeting PD1
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Jan 27, 2023

    Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

    Not yet recruiting
    • Metastatic Extracranial Malignant Solid Neoplasm
    • +3 more
    • Intestinal Low Dose Radiotherapy-1Gy
    • +3 more
    • Shantou, Guangdong, China
      Cancer Hospital, Shantou University Medical College
    Oct 7, 2023

    Neuroblastoma, Pediatric Solid Tumor Trial in Boston (procedure, biological, drug)

    Recruiting
    • Neuroblastoma
    • Pediatric Solid Tumor
    • Tissue collection
    • +3 more
    • Boston, Massachusetts
    • +1 more
    Oct 17, 2022

    Advanced Solid Tumors Trial in United States (mRNA-4359, Pembrolizumab)

    Recruiting
    • Advanced Solid Tumors
    • mRNA-4359
    • Pembrolizumab
    • San Francisco, California
    • +9 more
    Sep 7, 2022

    Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

    Recruiting
    • Sarcoma
    • HER-2 Protein Overexpression
    • cells
    • +3 more
    • Houston, Texas
      Texas Children's Hospital
    Dec 8, 2021

    Autoimmunity After Checkpoint Blockade

    Recruiting
    • Autoimmunity
    • +3 more
      • Philadelphia, Pennsylvania
        University of Pennsylvania - Abramson Cancer Center
      Nov 29, 2021

      MDS, Acute Myeloid Leukemia Trial in New Haven (AG-120, Nivolumab)

      Withdrawn
      • Myelodysplastic Syndromes
      • Acute Myeloid Leukemia
      • New Haven, Connecticut
        Yale Cancer Center
      Jan 6, 2022